Business Context and Reporting Period
This Form 8-K is a current report filed by Oncocyte Corporation (trading symbol: OCX) on April 11, 2024. The filing primarily announces the entry into a material definitive agreement for a private placement of equity securities and references the release of financial results for the fiscal year ended December 31, 2023.
Key Financial Metrics and Transaction Details
The filing details a private placement transaction with the following specific metrics:
- Securities Issued: 5,077,387 shares of Common Stock and pre-funded warrants to purchase up to 342,888 shares of Common Stock.
- Purchase Price: $2.9164 per Common Share and $2.9163 per Pre-Funded Warrant.
- Gross Proceeds: Approximately $15.8 million (before fees and expenses).
- Use of Proceeds: General corporate purposes, working capital, and the redemption of approximately $5 million in Series A Redeemable Convertible Preferred Stock.
- Debt/Liquidity Impact: The transaction is intended to bolster working capital and eliminate a specific preferred stock obligation due on April 15, 2024.
Note: This filing does not contain specific revenue, profit, cash flow, or margin figures for the company. These metrics are referenced as being contained in a separate press release (Exhibit 99.2) for the year ended December 31, 2023, which is incorporated by reference but not detailed in this text.
Material Changes and Agreements
The primary material change is the execution of a Securities Purchase Agreement with accredited investors. Key terms include:
- Closing Date: Expected on or about April 15, 2024, subject to customary conditions.
- Registration Rights: The Company agreed to file a registration statement for the resale of the securities within 30 days and use best efforts to have it declared effective within 60 days (or 75 days in the event of a full SEC review).
- Ownership Limitations: Beneficial ownership is limited to 4.99% (or 9.99% at the holder's election) immediately after exercise, with provisions to increase this limit upon 61 days' prior notice.
- Placement Agent: Needham & Company, LLC served as the exclusive placement agent.
Outlook, Risks, and Management Commentary
Management intends to use the net proceeds to fund general corporate purposes and working capital, specifically addressing the mandatory redemption of Series A Preferred Stock. The filing includes standard forward-looking statements regarding the closing of the transaction and the exercise of warrants.
Risks and Contingencies: The filing cautions that actual results may differ materially from forward-looking statements due to risks identified in the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The closing of the private placement is contingent upon the satisfaction of customary closing conditions.
Investor Verification Checklist
- Verify the final closing date of the private placement (expected April 15, 2024) and confirm the actual gross proceeds received.
- Review the press release dated April 12, 2024 (Exhibit 99.2) for specific revenue, net income, and cash flow figures for the year ended December 31, 2023, as these are not included in this 8-K text.
- Confirm the successful redemption of the Series A Redeemable Convertible Preferred Stock using the allocated proceeds.
- Monitor the status of the registration statement filing for the resale of the new shares and warrants, which is required within 30 days of the agreement date.
- Check for any updates on the beneficial ownership limits of the purchasers and potential dilution effects on existing shareholders.